BLASUBCUTANEOUSINJECTABLE
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
OMVOH (mirikizumab-mrkz) by Eli Lilly and Company is interleukin-23 antagonists [moa]. Approved for interleukin-23 antagonist [epc]. First approved in 2023.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OMVOH (mirikizumab-mrkz) is a monoclonal antibody that antagonizes Interleukin-23 (IL-23), a key cytokine driving inflammatory diseases. Approved by FDA on October 26, 2023, it is administered via subcutaneous injection. The drug targets patients with IL-23-driven immune-mediated conditions, blocking a central pathway in inflammatory disease pathogenesis.
Growth
Early-stage growth asset from Eli Lilly with moderate competitive pressure (30%), indicating active commercial expansion and team-building opportunities.
Mechanism of Action
Interleukin-23 Antagonists
Pharmacologic Class:
Interleukin-23 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
OMVOH offers career opportunity in a high-growth phase for a major global pharmaceutical company (Eli Lilly), with roles concentrated in commercial execution, competitive positioning, and market penetration. Working on this asset provides exposure to competitive dynamics in a crowded therapeutic class and the strategic challenge of differentiation in an established IL-23 market.
Brand Manager
Worked on OMVOH at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.